A propensity analysis of AURORA 1 suggested that initial therapy with LUPKYNIS® plus standard of care improved safety and demonstrated earlier reductions in proteinuria when compared to a conventional regimen consisting… Read More
Net loss for the first nine months of 2023 decreased by 44% as compared to the same period in 2022 Cash resources of $390.2 million as of September 30, 2023 expected to fund planned operations through at least the… Read More
VANCOUVER, BC, and BASEL, SWITZERLAND — Genevant Sciences, a leading nucleic acid delivery company with world- class platforms and an expansive lipid nanoparticle (LNP) patent portfolio, announced that it has… Read More
Clairvoyant Therapeutics announced it has reached an agreement in principle to base its European headquarters in Portugal as the flagship company in Empowered Startups’ Mental Health & Addiction Cluster. European… Read More
Vancouver, B.C. – Dr. Ghania Chikh has joined Acuitas Therapeutics, Inc. as Senior Director, Vaccine Development, Chief Scientific Officer Dr. Ying Tam recently announced. In this senior leadership role, Dr…. Read More
